MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics to Participate in Upcoming Investor Conferences

This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results

MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst

Analysts Set Maplight Therapeutics, Inc. (NASDAQ:MPLT) Target Price at $31.80

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics to Participate in Upcoming Investor Conferences

Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity

Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell?

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

MapLight Therapeutics valued at $787 million as shares jump in Nasdaq debut

MapLight Therapeutics Announces Pricing of Initial Public Offering

US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On

MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments